Ipsen S.A. (OTCMKTS:IPSEY) Sees Significant Drop in Short Interest

Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) was the target of a large drop in short interest in May. As of May 15th, there was short interest totalling 1,100 shares, a drop of 26.7% from the April 30th total of 1,500 shares. Approximately 0.0% of the company's stock are short sold. Based on an average trading volume of 4,200 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Ipsen in a report on Wednesday, April 2nd.

Ipsen Price Performance

OTCMKTS:IPSEY traded down $0.10 during midday trading on Wednesday, hitting $29.50. 1,297 shares of the company were exchanged, compared to its average volume of 4,924. The company has a fifty day simple moving average of $28.41 and a 200 day simple moving average of $29.15. Ipsen has a fifty-two week low of $25.11 and a fifty-two week high of $33.97.

Ipsen Increases Dividend

The business also recently announced a dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be paid a $0.2896 dividend. The ex-dividend date is Monday, June 9th. This represents a dividend yield of 0.97%. This is a positive change from Ipsen's previous dividend of $0.23.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.